Key Drivers
- Strong ROIC
- Falling Debt
- Lower Cash
AIAI Summary
ATR is best viewed as a pharmaceutical-delivery growth story trading at an execution discount: accumulating shares is most compelling only if injectable capacity utilization and Beauty/Closures repairs begin validating a return to broad-based margin growth, while prolonged destocking or underutilization could drive further multiple compression.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong ROIC
- •Falling Debt
- •Lower Cash
ATR shows strong returns, positive free cash flow, and declining debt, but moderating margins, lower cash, intangible-heavy equity, and a premium valuation warrant cautious monitoring.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Oversold momentum
- •Key support
ATR remains bearish over the last month, but deeply oversold momentum may support a rebound if price holds $122.11 and breaks above $124.90–$125.50.
RSI near 18 signals unusually oversold conditions
Sentiment & News
Key News Insights:
- •New Institutional Stakes
- •Tidal Position Cut
- •Healthcare Conferences
AptarGroup drew mixed institutional activity and healthcare-conference visibility, with no material operating or guidance updates reported.
The news is broadly neutral for ATR, signaling investor interest but lacking fundamental catalysts
Similar Companies in Healthcare
Other companies in the same sector with AI ratings